Esperion Therapeutics (NASDAQ:ESPR – Get Rating) released its results on Tuesday. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, beating Thomson Reuters consensus estimate of ($1.04) by $0.11, MarketWatch Earnings reports. The company posted revenue of $18.84 million for the quarter, versus analyst estimates of $15.41 million. During the same quarter of the previous year, the company posted EPS ($3.50). The company’s revenue for the quarter increased 136.1% year over year.
ESPR stock traded down $0.33 on Tuesday, hitting $6.06. The company had a trading volume of 49,109 shares, compared to its average volume of 1,242,130. Esperion Therapeutics has a 1-year low of $3.28 and a 1-year high of $27.28. The company’s fifty-day moving average is $4.99 and its 200-day moving average is $5.69.
The ESPR has been the subject of several recent analyst reports. Credit Suisse Group lowered its price target on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a Friday, January 14 research report. HC Wainwright kicked off Esperion Therapeutics coverage in a research report Thursday, March 10. They set a “buy” rating and a target price of $22.00 on the stock. StockNews.com began covering Esperion Therapeutics in a research report on Thursday, March 31. They put a “sell” mark on the stock. Finally, Northland Securities lowered its price target on Esperion Therapeutics from $10.00 to $5.00 in a Wednesday, January 12 research note. Three equity research analysts gave the stock a sell rating, three gave the company a hold rating and four gave the company a buy rating. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.50.
Hedge funds have recently been buying and selling stocks. Bank of New York Mellon Corp increased its stake in Esperion Therapeutics by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 92,049 shares of the biopharmaceutical company valued at $1,109,000 after buying 8,292 additional shares last quarter. Cubist Systematic Strategies LLC increased its stake in Esperion Therapeutics by 33.9% in the fourth quarter. Cubist Systematic Strategies LLC now owns 196,745 shares of the biopharmaceutical company valued at $984,000 after purchasing an additional 49,802 shares last quarter. Public Employees Retirement System of Ohio increased its stake in Esperion Therapeutics by 204.6% in the 4th quarter. The Ohio Public Employees Retirement System now owns 168,552 shares of the biopharmaceutical company valued at $843,000 after purchasing an additional 113,214 shares last quarter. JPMorgan Chase & Co. increased its stake in Esperion Therapeutics by 35.7% in the 4th quarter. JPMorgan Chase & Co. now owns 117,303 shares of the biopharmaceutical company valued at $587,000 after buying 30,848 additional shares last quarter. Finally, Wells Fargo & Company MN increased its stake in Esperion Therapeutics by 160.9% in the second quarter. Wells Fargo & Company MN now owns 26,990 shares of the biopharmaceutical company valued at $572,000 after buying 16,644 additional shares last quarter.
Esperion Therapeutics Company Profile (Get a rating)
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with elevated low-density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Get news and reviews for Esperion Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Esperion Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.